Paraoxonase 1 Activity is Associated with Interleukin‑6 Levels in Type 2 Diabetes: Effects of Age and Gender

Armin Nikzad, Ahad Alizadeh, Saeid Abediankenari, Zahra Kashi, Abdolkarim Mahrooz


Background: A further understanding of the mechanisms linking inflammation to T2D and related complications can help prevent or control this silent but dangerous disease. This study was conducted to determine the association between paraoxonase 1 (PON1) activity and interleukin‑6 (IL‑6) in type 2 diabetes (T2D). Furthermore, we have evaluated the role of age and gender in the relationship between the PON1 activity and IL‑6. Methods: A total of 105 people with T2D were enrolled in this study. IL‑6 levels were determined using ELISA. For the PON1 activity assay, the hydrolysis rate of the substrate phenylacetate was spectrophotometrically assayed in serum at 270 nm. The determined velocities were the initial velocities of substrate hydrolysis. Results: PON1 activity was negatively correlated with IL‑6 in total data (r = −0.34, P = 0.001). In both groups with age ≥50 and <50 years, PON1 activity was negatively correlated with IL‑6, but the correlation was significant in patients aged 50 years and above (r = −0.358, P = 0.005) compared with patients with age <50 years. In both women and men, PON1 activity was negatively correlated with IL‑6, but the correlation was significant in women (r = −0.318, P = 0.006) in comparison with men. Conclusions: Inverse association between PON1 activity and IL‑6 in T2D may represent the oxidative–inflammatory interaction in this disease. Our findings highlight that at older ages and in women, the associations between lower PON1 activity and higher IL‑6 concentrations are more evident, and this should be considered in patients with T2D.


Age; gender; interleukin‑6; paraoxonase 1; type 2 diabetes

Full Text:



Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2

diabetes and its impact on the immune system. Current Diabetes

Rev 2020;16:442‑9.

Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New

insights into oxidative stress and inflammation during diabetes

mellitus‑accelerated atherosclerosis. Redox Biol 2019;20:247‑60.

Ahmadi M, Mahrooz A, Abediankenari S, Hayati Roodbari N.

Association of rs11558471 in SLC30A8 gene with interleukin

serum levels and insulin resistance in Iranian patients with

type 2 diabetes. Iran J Immunol 2020;17:215‑25.

Tsalamandris S, Antonopoulos AS, Oikonomou E,

Papamikroulis G‑A, Vogiatzi G, Papaioannou S, et al. The

role of inflammation in diabetes: Current concepts and future

perspectives. Eur Cardiol Rev 2019;14:50.

Calle M, Fernandez M. Inflammation and type 2 diabetes.

Diabetes Metab 2012;38:183‑91.

Mahrooz A, Mackness M, Bagheri A, Ghaffari‑Cherati M,

Masoumi P. The epigenetic regulation of paraoxonase 1 (PON1)

as an important enzyme in HDL function: The missing link

between environmental and genetic regulation. Clin Biochem


Variji A, Shokri Y, Fallahpour S, Zargari M, Bagheri B,

Abediankenari S, et al. The combined utility of

myeloperoxidase (MPO) and paraoxonase 1 (PON1) as

two important HDL‑associated enzymes in coronary artery

disease: Which has a stronger predictive role? Atherosclerosis


Aharoni S, Aviram M, Fuhrman B. Paraoxonase 1 (PON1)

reduces macrophage inflammatory responses. Atherosclerosis


Mahrooz A, Shokri Y, Variji A, Zargari M, Alizadeh A,

Mehtarian E. Improved risk assessment of coronary artery

disease by substituting paraoxonase 1 activity for HDL‑C: Novel

cardiometabolic biomarkers based on HDL functionality. Nutr

Metab Cardiovasc Dis 2021;31:1166‑76.

Shokri Y, Variji A, Nosrati M, Khonakdar‑Tarsi A, Kianmehr A,

Kashi Z, et al. Importance of paraoxonase 1 (PON1) as an

antioxidant and antiatherogenic enzyme in the cardiovascular

complications of type 2 diabetes: Genotypic and phenotypic

evaluation. Diabetes Res Clin Pract 2020;161:108067. doi:

1016/j.diabres. 2020.108067.

Akbari M, Hassan‑Zadeh V. IL‑6 signalling pathways and

the development of type 2 diabetes. Inflammopharmacology


Ershler WB, Keller ET. Age‑associated increased interleukin‑6

gene expression, late‑life diseases, and frailty. Ann Rev Med


Kristiansen OP, Mandrup‑Poulsen T. Interleukin‑6 and

diabetes: The good, the bad, or the indifferent? Diabetes

;54(Suppl 2):S114‑24.

Zargari M, Sharafeddin F, Mahrooz A, Alizadeh A, Masoumi P.

The common variant Q192R at the paraoxonase 1 (PON1)

gene and its activity are responsible for a portion of the

altered antioxidant status in type 2 diabetes. Exp Biol Med


Leinonen E, Hurt‑Camejo E, Wiklund O, Hultén LM, Hiukka A,

Taskinen M‑R. Insulin resistance and adiposity correlate with

acute‑phase reaction and soluble cell adhesion molecules in

type 2 diabetes. Atherosclerosis 2003;166:387‑94.

Mahrooz A, Hashemi‑Soteh MB, Heydari M, Boorank R,

Ramazani F, Mahmoudi A, et al. Paraoxonase 1 (PON1)‑L55M

among common variants in the coding region of the paraoxonase

gene family may contribute to the glycemic control in type 2

diabetes. Clin Chim Acta 2018;484:40‑6.

Brinholi FF, Noto C, Maes M, Bonifácio KL, Brietzke E,

Ota VK, et al. Lowered paraoxonase 1 (PON1) activity is

associated with increased cytokine levels in drug naïve first

episode psychosis. Schizophr Res 2015;166:225‑30.

Dehkordi AA, Nayeri H, Naderi G, Dinani NJ, Boshtam M.

Interleukin‑6 reduces paraoxonase‑1 activity in a dose‑dependent

manner; evidence for a potential novel lipoprotein‑based

modulatory mechanism. Atherosclerosis 2016;252:e113‑4.

Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M,

Orasanu G, et al. Reciprocal and coordinate regulation of serum

amyloid A versus apolipoprotein AI and paraoxonase‑1 by

inflammation in murine hepatocytes. Arterioscler Thromb Vasc

Biol 2006;26:1806‑13.

Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized

phospholipids induce changes in hepatic paraoxonase and ApoJ

but not monocyte chemoattractant protein‑1 via interleukin‑6.

J Biol Chem 2001;276:1923‑9.

Albani D, Batelli S, Polito L, Prato F, Pesaresi M, Gajo GB,

et al. Interleukin‑6 plasma level increases with age in an Italian

elderly population (“The Treviso Longeva”–Trelong–study) with

a sex‑specific contribution of rs1800795 polymorphism. Age


Mahrooz A, Alizadeh A, Gohari G. The salt stimulation property

of serum paraoxonase (PON1) could be a valuable factor in

evaluating the enzyme status in ischemic stroke: The role of

activity‑determined PON1 192Q/R phenotypes. J Neurol Sci


Kumar D, Rizvi SI. Age‑dependent paraoxonase 1 (PON1)

activity and LDL oxidation in Wistar rats during their entire

lifespan. ScientificWorldJournal 2014;2014:538049. doi:


Marek G, Ściskalska M, Grzebieniak Z, Milnerowicz H. Decreases

in paraoxonase‑1 activities promote a proinflammatory effect of

lipids peroxidation products in non‑smoking and smoking patients

with acute pancreatitis. Int J Med Sci 2018;15:1619‑30.

O’Connor M‑F, Motivala SJ, Valladares EM, Olmstead R,

Irwin MR. Sex differences in monocyte expression of IL‑6: Role

of autonomic mechanisms. Am J Physiol Regul Integr Comp

Physiol 2007;293:R145‑51.